RenovoRx (RNXT) Common Equity (2020 - 2026)
RenovoRx (RNXT) posted Common Equity of $11.3 million for Q1 2026, up 107.76% sequentially from $5.4 million in Q4 2025, and down 14.38% YoY from $13.2 million in Q1 2025.
RenovoRx (RNXT) Common Equity (2020 - 2026) Analysis & Trends
RenovoRx has reported Common Equity for 7 years, with the latest figure at $11.3 million in Q1 2026.
- Quarterly Common Equity fell 14.38% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 14.38% YoY) and the FY2025 annual result came in at $5.4 million, up 21.08% from the prior year.
- Common Equity grew to $11.3 million in Q1 2026 per RNXT's latest filing, from $5.4 million in the prior quarter.
- Over five years, Common Equity peaked at $13.2 million in Q1 2025 and troughed at $6000.0 in Q3 2023.
- A 5-year average of $6.8 million and a median of $7.1 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 99.93% in 2023, then jumped 117750.0% in 2024.
- Over 5 years, Common Equity stood at $6.2 million in 2022, then slumped by 51.32% to $3.0 million in 2023, then soared by 49.27% to $4.5 million in 2024, then climbed by 21.08% to $5.4 million in 2025, then soared by 107.76% to $11.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $11.3 million, $5.4 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.65 Bn | 131.79 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.08 Bn | 78.09 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 63.25 Bn | 58.11 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.26 Bn | 27.95 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.96 Bn | 10.57 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.35 Bn | - | 9.79 Bn |
| 10 | RenovoRx | 60.54 Mn | 60.54 Mn | 766,000.00 | 8.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.98 Mn |
| Mar 31, 2026 | 11.27 Mn |
| Dec 31, 2025 | 5.42 Mn |
| Sep 30, 2025 | 8.08 Mn |
| Jun 30, 2025 | 10.64 Mn |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 4.48 Mn |
| Sep 30, 2024 | 7.07 Mn |
| Jun 30, 2024 | 9.27 Mn |
| Mar 31, 2024 | 1.77 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Sep 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 3.26 Mn |
| Dec 31, 2022 | 6.16 Mn |
| Sep 30, 2022 | 8.15 Mn |
| Jun 30, 2022 | 10.12 Mn |
| Mar 31, 2022 | 12.54 Mn |
| Dec 31, 2021 | 15.35 Mn |
| Sep 30, 2021 | 17.55 Mn |